An Intermediate Size Expanded Access Protocol of Elamipretide

Status Available

Clinical Trial Summary

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program. The treating physician must contact StealthBiotherapeutics using the Expanded Access Program Contacts provided. Elamipretide will only be made available after careful review of an individual request submitted by the treating physician. The initiation and conduct of the treatment with elamipretide for an individual patient, and compliance with this treatment guideline, will be under the full and sole responsibility of the treating physician.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04689360
Study type	Expanded Access
Source	Stealth BioTherapeutics Inc.
Contact	Donna Cowan
Phone	617.600.6888
Email	donna.cowan@stealthbt.com
Status	Available
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03388528` - Low Residue Diet Study in Mitochondrial Disease	N/A
Completed	`NCT04378075` - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy	Phase 2/Phase 3
Completed	`NCT03678740` - Diagnostic Odyssey Survey 2
Recruiting	`NCT06051448` - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).	Phase 1/Phase 2
Completed	`NCT02909400` - The KHENERGY Study	Phase 2
Completed	`NCT02398201` - A Study of Bezafibrate in Mitochondrial Myopathy	Phase 2
Completed	`NCT03857880` - Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
Not yet recruiting	`NCT06450964` - Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
Completed	`NCT04165239` - The KHENERGYZE Study	Phase 2
Completed	`NCT02284334` - Glycemic Index in Mitochondrial Disease
Recruiting	`NCT06080568` - Human Mitochondrial Stress-driven Obesity Resistance
Recruiting	`NCT06080581` - Mitochondrial Dysfunctions Driving Insulin Resistance
Recruiting	`NCT04802707` - Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome	Phase 2
Completed	`NCT04594590` - Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Completed	`NCT04580979` - Natural History Study of FDXR Mutation-related Mitochondriopathy
Withdrawn	`NCT03866954` - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy	Phase 2
Recruiting	`NCT04113447` - Mitochondrial Donation: An 18 Month Outcome Study.
Enrolling by invitation	`NCT04734626` - CrCest Study in Primary Mitochondrial Disease
Completed	`NCT03832218` - Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies	N/A
Terminated	`NCT02473445` - A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease	Phase 2